Protillion Biosciences raises $18M in financing to support therapeutic biomarker discovery

By The Science Advisory Board staff writers

December 19, 2022 -- Protillion Biosciences, a privately held biotech company launched in 2019 to identify and optimize new protein therapeutics, on Monday announced the completion of an $18 million Series A financing from Arch Venture Partners and Illumina Ventures.

Protillion said that its platform enables commercial drug discovery partners to perform quantitative analysis on complete protein libraries, producing actionable insights in days rather than the months required using current industry best practices. The company said its technology can generate and analyze large experimental datasets at high amino acid resolution, enabling novel machine-learning approaches to antibody and binder discovery.

The funds will be used to scale up its hardware infrastructure and development teams to meet the demand for future partnerships in therapeutic antibody discovery. Protillion is currently identifying opportunities to accelerate discovery processes for potential pharmaceutical partners through its technology.

Protillion's technology approaches for drug discovery unite an array of interdisciplinary fields, including protein engineering, next-generation sequencing technology, molecular biology, in vitro transcription and translation, computational biology, software development, and various engineering disciplines.

"For the first time, quantitative binding measurements for millions of biologic candidates can be seen upfront, and big data is available much earlier in the discovery process," Protillion co-founder and CEO Curtis Layton said in a statement.

Dewpoint Therapeutics obtains $150M in series C financing
Dewpoint Therapeutics, a company focused on developing medications to treat diseases resulting from the dysregulation of biomolecular condensates, has...
ONI closes $75M series B funding
ONI, known for the Nanoimager microscopy platform, closed a $75 million series B financing round. The proceeds will be used to grow ONI's commercial...
Halo Labs launches next-gen instruments for therapeutic developers
Halo Labs has launched its latest products, the Aura PTx that analyzes degraded excipients in protein therapeutics, and Aura+, an all-in-one drug product...
20n Bio raises $3.3M to advance computational design of protein therapeutics
20n Bio (20n), an artificial intelligence (AI)-powered drug discovery company focused on designing new proteins for therapeutics, has raised a $3.3 million...
Rebus Bio acquires EEL Transcriptomics
Rebus Bio, an Illumina Ventures-backed company, announced that it has acquired the intellectual property and related assay assets of EEL Transcriptomics,...
Startup Mozart targets autoimmune, inflammatory diseases
Biopharmaceutical startup Mozart Therapeutics has launched with a focus on developing therapeutics for autoimmune and inflammatory diseases.
Illumina Ventures raises $325M to fund health startups
Illumina Ventures has raised $325 million for its second investment fund, which will support healthcare startups.

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter